SilkTears, LLC, a privately held, research-based and product-driven biotechnology company, is working on advances in protein-based excipient technology that may allow for the development of artificial tear products that will more closely represent certain characteristics of the natural makeup of the tear film, and may help the significant population of patients suffering from dry eye syndrome.
